Pancragen: The Definitive Guide

What is Pancragen?

Pancragen is a very short lab-made peptide, a chain of four amino acids, that people take hoping to support the pancreas: mostly for type 2 diabetes and blood sugar, and sometimes for chronic pancreatitis and digestion.

It comes from a Russian research program led by Vladimir Khavinson, whose group calls these short peptides bioregulators and names each one after the organ it is meant to target: “pancra” for the pancreas. The group's 2003 patent describes the chain lysine, glutamic acid, aspartic acid and tryptophan, written Lys-Glu-Asp-Trp or KEDW, with an amide (a small chemical cap) on the end. [1], [2], [3]

The name covers several different products. In Russia, Pancragen is a dietary-supplement capsule declaring 100 mcg of a “peptide complex” made of those four amino acids. A Russian liquid called Pangluin Forte lists the same peptide in an unstated amount among 12 plant extracts. Western peptide sellers offer 10–20 mg vials of powder for injection as “research” chemicals. None is an approved medicine. [4], [5], [6], [7]

Two other Russian pancreas products are often confused with it. Suprefort is a natural peptide extract from animal pancreas, and Pancramin is a cattle-pancreas extract; neither is the lab-made KEDW peptide. [8], [9]

Doserly

One name, several products

Product labels and protocol websites

Capsules (Russia)

What it is: Dietary-supplement capsule, 0.2 g, declaring 100 mcg of peptide complex made of lysine, glutamic acid, aspartic acid and tryptophanRoute: Oral (swallowed) with mealsLabel schedule: 1–2 capsules, 1–2 times a day, for 1 month; repeat after 4–6 monthsDaily amount: 100–400 mcgHuman data: Small developer-run reports (institute report 2007; Kyiv study used 100 mcg twice daily)

Research vials (online)

What it is: 10–20 mg of powder, sold as a research chemical; amide or free-acid form varies by sellerRoute: Subcutaneous injection (into the fatty layer under the skin), according to websitesWebsite schedule: Most often 1–2 mg once daily for 10–20 daysDaily amount: 1–2 mg (range 0.1–5 mg)Human data: None for these amounts

Pangluin Forte liquid (Russia)

What it is: Liquid with plant extracts listing Lys-Glu-Asp-Trp amide (“AA-11”)Route: OralLabel schedule: 1 teaspoon (5 mL) once daily with a meal, for 1 monthDaily amount: Peptide amount not statedHuman data: None

Not Pancragen

Suprefort: Natural peptide extract from pancreas (“complex A-1”)Pancramin: Peptide extract from cattle pancreas

The capsule declares micrograms, the vial websites describe milligrams, the liquid states no amount, and two pancreas extracts share the shelf but are different substances.

Typical Pancragen Protocols

The most common capsule protocol in the reviewed sources is 1–2 capsules, 1–2 times a day with meals (100–400 mcg a day), for one month, repeated after 4–6 months. Russian seller and clinic pages repeat the same label wording, so it is one source copied several times rather than several independent opinions. [4], [12], [13]

Titration Changing the amount in steps

The label does not step the amount up or down; it gives a range. The developer institute's report adds that people with type 2 diabetes should take it “under control of blood glucose”, and in its own study the doses of diabetes medicines were adjusted as blood sugar fell. [4], [10]

Breaks and cycles

One course of about a month, then a repeat course after 4–6 months according to the label, or after 3–6 months according to the institute report: about two courses a year. [4], [10]

Timing

With meals, according to the label. [4] The abstract on the separately named “forte” product reports morning and evening doses but does not state the route. [14]

Read the units: mcg means micrograms; 1 mg equals 1,000 mcg. The capsule itself weighs 0.2 g (200 mg), but only 100 mcg of that is the declared peptide complex; the rest is filler such as cellulose, sugar and starch. Newer 0.275 g capsules and tablets are also listed, and the pages we could read do not state their peptide content. [4], [15]

Before you compare any of these numbers, three cautions. First, every diabetes study gave Pancragen on top of insulin or diabetes pills, including sulfonylureas, and several lowered those drugs as blood sugar fell, so anyone taking diabetes medicine faces a real risk of low blood sugar and should involve the prescriber before starting (see the risks). Second, it has not been tested as a treatment for a pancreatitis attack or for raised pancreas enzymes, which need medical assessment. Third, the capsule label lists pregnancy and breastfeeding as reasons not to use it. [11], [1], [10], [4]

Each row is a complete schedule from one source, so its amount and duration belong together. Low, mid and high are alternatives, not steps to move through. These capsule schedules come from the supplement label and small studies run by the developer's network; the cited references give the full details.

What about injectable vials?

The most common injectable pattern in the reviewed sources is 1–2 mg once a day by subcutaneous injection for 10–20 days, repeated a few times a year. Other pages range from 100 mcg to 5 mg a day, and one database says openly that the 1–2 mg, 10-day course is a convention shared across this whole family of peptides, not a finding. [6], [17], [18], [19], [7], [16]

None of these injected amounts has been studied in people. The only injections given to people in the research were 10 mcg a day into a muscle (intramuscular) for 10 days to 3 weeks, so the usual 1–2 mg a day is 100 to 200 times that amount. [1], [20] It is also 2.5 to 20 times the capsule label's 100–400 mcg a day by mouth. [4]

In community education groups, educators and members mostly apply a general rule for every bioregulator: 1–2 mg a day by subcutaneous injection for 10–30 days, two or three times a year. One member explained that the figure was worked out from capsule products, and one educator's template gives a higher 2–5 mg without saying whether that is per day or per course. None of them cited a Pancragen study.

Where protocols differ: products, units, course length and breaks ↓

What is Pancragen commonly used for?

People usually look into Pancragen because of blood sugar. They have type 2 diabetes that is getting harder to control, prediabetes or insulin resistance, or they want to protect the pancreas as they age. A smaller group is interested because of chronic pancreatitis, bloating and poor digestion.

A Russian product directory files the capsule under type 2 diabetes and unspecified pancreas disease, and the developer's patent describes it as a peptide “regulating blood glucose level in diabetes mellitus”. The reports below describe that interest and what small studies measured; they do not establish that Pancragen treats or prevents any of these conditions. [4], [2]

Type 2 diabetes and blood sugar

This is where most of the human research sits. A randomized study in Kyiv added Pancragen by mouth for 3 weeks to glibenclamide (a sulfonylurea) in older adults whose diabetes was poorly controlled. The developer institute's own report gave capsules to people with type 2 diabetes on usual treatment. Both describe lower blood sugar and, in the institute report, lower doses of diabetes medicine. [11], [27], [10]

The reported changes were short-term and varied across reports, and no study reported a change in HbA1c, the standard long-term measure of diabetes control. What the human reports can and cannot show.

Type 1 diabetes and insulin needs

The patent's human example included 23 people with type 1 diabetes among 36 hospital patients, most of them on insulin. The patent reports that fewer treated patients needed more insulin. That is a single inventor-reported example, and no other study tested type 1 diabetes. Pancragen does not replace insulin, and stopping insulin in type 1 diabetes is dangerous. [1]

Chronic pancreatitis and digestion

The developer institute's 2007 report gave capsules to 18 people with chronic pancreatitis in remission (a quiet period between flare-ups), alongside usual care. It reports fewer digestive complaints such as belching and bloating, and blood-test changes. It was not published in a journal, and the enzyme results were only trends. [10] Nothing has been tested during an acute attack.

Prediabetes and the aging pancreas

Some pages promote Pancragen for “pancreatic aging” in older people. A 2013 series gave a separately named “forte” product to 12 older adults with impaired glucose tolerance (blood sugar that rises higher than normal after a sugar drink), and half improved. Only the abstract is available, and it describes no comparison group. [14] The aging idea otherwise rests on cells grown in a dish and on old monkeys. How it might work.

Other uses you may come across

Some pages say Pancragen regenerates insulin-making beta cells, restores pancreatic cell function or prevents pancreatic cancer, and one public reply claimed a peptide combination including it would cut cancer risk in half. Those claims go far beyond the evidence. The cell findings behind them come from cells in a dish, including a pancreatic cancer cell line, and from rats; none was tested in people. [6], [7], [28], [29], [30], [1]

See the human research or explore how it might work.

Where do Pancragen protocols differ?

The capsule label is easy to summarize. The disagreements start when a page mixes up the products, the units or the route. Here is what varies and why it matters.

Capsule, vial or liquid: which product is the number for?

Always check this first. The capsules declare 100 mcg of peptide complex each. Research vials contain 10–20 mg (10,000–20,000 mcg) of powder. Pangluin Forte, the liquid, is taken as one teaspoon (5 mL) a day with a meal for a month, but its label does not say how much peptide a teaspoon holds, so it cannot be compared with either. [4], [6], [5], [31] Suprefort and Pancramin capsules are different substances altogether. Is Pancragen the same as Suprefort?

Why do some websites give 10–20 mg capsules?

Several English pages say each Russian capsule holds “approximately 20 mg of active peptide” or that 1–2 capsules give 10–20 mg a day. Every manufacturer document found says 100 mcg per capsule, so those figures are 100 to 200 times too high; they may confuse the 0.2 g capsule weight or a vial size with the peptide content. [22], [21], [19], [4], [10] An educational lesson in a community education group repeated a similar milligram capsule figure.

Micrograms in the studies, milligrams on the vial websites

Every amount that traces back to a Pancragen study is in micrograms. The injection pages that use milligrams have no Pancragen study behind them. The figure below puts the numbers on one scale.

Doserly

Micrograms in the studies, milligrams on the vial websites

Patent, product label, small human studies, an animal study and protocol websites; no dose-finding study exists.

From studies and the label

Patent, injected into a muscle (10 days)

10 mcg a day, injected into a muscle for 10 days.

Old monkeys, into a muscle (per animal, 10 days)

50 mcg a day into a muscle per animal for 10 days; animal, not a human dose.

Capsule label, by mouth

100–400 mcg a day by mouth.

Kyiv study, by mouth (3 weeks)

200 mcg a day by mouth for 3 weeks.

“Forte” product, 2013 series (4 weeks)

1,000 mcg a day for 4 weeks; a separately named product, route not stated.

From vial websites (no Pancragen study behind them)

Injection pages, under the skin

100–5,000 mcg a day under the skin; most common 1,000–2,000 mcg.

The usual 1–2 mg a day is 100 to 200 times the only injected human dose and 2.5 to 20 times the capsule label's daily amount.

Every amount traced to a Pancragen study or label is in micrograms; the milligram injection amounts have no Pancragen study behind them.

Which amounts were actually given to people?

The patent itself claims 0.1–30 mcg per kg of body weight at least once a day, by mouth or by injection. Its English translation prints the claim as “mg/kg” in one place, which is 1,000 times higher; the Russian original and the rest of the English text say micrograms. [1], [2]

Is the number for one dose or the whole day?

Two capsules twice a day is four capsules, or 400 mcg, for the day. The label's “1–2 capsules, 1–2 times a day” therefore covers 100 to 400 mcg a day. The Kyiv study's 100 mcg twice daily is 200 mcg a day, and the forte series' 500 mcg twice daily is 1,000 mcg a day of a different product. For injections, most pages give a single daily amount, so the dose and the daily total are the same number. [4], [11], [14]

How many days, and how often is a course repeated?

The studies ran for 10 days (patent), 3 weeks (Kyiv), 20–30 days (institute report) and 4 weeks (forte series). The label says one month. Injection pages mostly use 10–20 days, one uses 20–30 days, and community education groups use 10–30 days. [1], [11], [10], [14], [4], [6], [7]

Repeats vary from every 2–6 months to once or twice a year. One protocol page's header gives an 8–12 week cycle while its own rows say 10 or 28 days, and in community education groups one member planned 60 days of daily injections. These are different conventions, not results from a trial comparing course lengths; nothing shows that a longer course works better. [16], [18], [25]

Do sources start low and step up?

Almost none do. The label and most injection pages use one fixed amount for the whole course. One protocol page describes an optional start of 800 mcg a day for 10 days, then 200–400 mcg a day for 20 days, and calls this front-loading (a loading phase) “weakly supported”. [32] In the studies, it was the diabetes medicines, not Pancragen, whose doses were adjusted. [1], [10]

How do milligrams convert to syringe units?

Injection pages often give amounts as “units” on an insulin syringe. A U-100 syringe holds 100 units per millilitre, so units measure volume, not an amount of Pancragen. How much Pancragen each unit holds depends on how much water was added to the vial.

For example, a 10 mg vial mixed with 2 mL of water holds 5 mg per mL, so 1 mg is 0.2 mL, or 20 units; this is the example one protocol page uses. The same 1 mg from a 20 mg vial mixed with 2 mL is only 10 units. Doserly's reconstitution calculator works this out for any vial and shows each step. [6], [18] For people who also inject insulin, the units on a syringe say nothing about which substance is inside or how strong it is.

What happens when you stop Pancragen?

Only the developer's network has looked, and only for a few weeks. No study reports withdrawal effects or a rebound, but none was designed to look for them. [27], [10], [40]

• Kyiv study. Two weeks after the 3-week course ended, the extra fall in blood sugar was still present in 9 of 16 people (the paper prints this as 60%; 9 of 16 is 56%). Everyone kept taking glibenclamide. [27], [11]
• Institute report. It says blood sugar in the treated group stayed stable for 2–3 months after the course, without giving the numbers. [10]
• Animals. In old monkeys, the improvement after a sugar load was similar 3 weeks after the last injection. In the patent's diabetic rats, glucose tolerance was still better 44 days after the course. [40], [41], [1]
• Repeat courses. The label suggests another course after 4–6 months, and the institute report after 3–6 months. Neither explains why, and no study has tested a second course. [4], [10]

If diabetes medicine doses were lowered during a course, blood sugar could rise again once any effect wears off, so the stopping point is a time to recheck readings with the prescriber rather than a time to stop monitoring.

Do capsules and injections of Pancragen behave the same way?

No one has measured this in any species. An oral capsule has to survive stomach acid and digestive enzymes and then cross the gut wall before anything reaches the blood. A subcutaneous injection skips digestion and is absorbed from the fatty layer under the skin; an intramuscular injection is absorbed from muscle. Those are different starting points, so a matching amount would not mean a matching exposure, and here the amounts do not even match.

Bioavailability is how much of a dose reaches the blood in the form being measured. For Pancragen it is unknown for every route. A 2005 abstract describes the amide form as “protected from the effects of gastrointestinal proteinases” (gut enzymes that break down proteins) but reports no experiment showing it, and a 2023 computer-modelling study predicted that it could fit a gut transporter protein called PEPT1. A prediction is not a measurement of absorption. [42], [43]

How long does Pancragen last in the body?

Nobody knows. No study has measured its half-life or blood levels in people or animals, and no stability test in blood or gut fluid has been published. [43], [42] The effects that lasted weeks after the monkey and Kyiv courses are about blood sugar, not about how long the peptide stays in the body. [40], [27]

Does it reach the pancreas?

Unknown. No study has tracked where Pancragen goes in the body. The idea that each bioregulator acts on its own organ comes from early laboratory work. In one experiment, small pieces of rat pancreas grew more in a dish exposed to 0.05 nanograms per mL of Pancragen. [44]

Amide or free acid: is every product the same molecule?

Not necessarily. The patent's molecule has an amide cap on its last amino acid (H-Lys-Glu-Asp-Trp-NH2), and the medical indexing of the papers uses both the amide and the uncapped “free acid” form. At least one seller offers the free acid, the Russian capsule lists four amino acids without giving their order, and one app page gives an entirely different sequence. No public test shows which molecule any product contains, or how much. [1], [45], [6], [4], [38]

How should Pancragen be stored, and how long does it last?

It depends on the product. The capsules come with storage instructions on the label; for injectable vials, nobody has published a stability test.

• Capsules. The label says to keep them in a dry place, protected from light, at 2–25 °C (36–77 °F) and out of children's reach, with a shelf life of five years. [4], [12]
• Vial powder, before mixing. Protocol pages say to keep the freeze-dried powder frozen at −20 °C (−4 °F) or at least refrigerated, away from light. [6], [18], [7]
• After mixing. Once the powder is mixed with liquid (reconstituted), the pages say to refrigerate it at 2–8 °C (36–46 °F), but their “use within” times range from 14 days to 45 days. None cites a stability test of Pancragen. [25], [34], [6], [18]

The capsules' five-year shelf life is the manufacturer's statement, and the vial times are website claims. Health Canada warns that unauthorized injectable peptides may not have been made or stored safely, and cold storage cannot tell you what is in a vial (see product quality). [46]

What do we actually know about Pancragen in people?

There are four small sources of human data, and all come from the developer's own network in St Petersburg and its collaborators in Kyiv. Everyone kept their usual diabetes or pancreatitis treatment. Only the patent example used a placebo, none describes hiding who got the peptide, and none says how side effects were looked for. ClinicalTrials.gov has no Pancragen study. [1], [10], [11], [14], [47]

What did the human reports find?

All the reports that mention safety say no side effects were seen, without saying how they were looked for. [10], [11], [20]

Doserly

Four sources of human data, not six

Human reports (small, developer-run)

2003–2004 · Patent example

People: 36 inpatients with type 1 or type 2 diabetesDesign: Randomly split; 16 injected 10 mcg daily for 10 days vs 16 salt-water placebo; 4 on tabletsResult: Insulin dose lowered in 8 of 16 vs 0 of 16Labels: Placebo, Inventor data

2007 · Institute report

People: 18 chronic pancreatitis; 24 type 2 diabetesDesign: Capsules plus usual care vs usual care (14; 19); not randomized, unpublishedResult: Fewer digestive complaints; fasting sugar 7.9 to 5.8 vs 8.2 to 6.6 mmol/LLabels: No placebo, Unpublished

2010 · 2011 · 2019 · Kyiv study (one study, three reports)

People: 30 older adults with type 2 diabetes on glibenclamideDesign: Randomized, open: 16 added 100 mcg by mouth twice daily for 3 weeks vs 14 glibenclamide alone; the 2019 abstract reports 10 mcg into a muscle plus 200 mcg by mouth dailyResult: Fasting sugar 9.4 to 8.5 vs 9.1 to 9.0 mmol/LLabels: Randomized, No placebo

2013 · “Forte” series

People: 12 older adults with impaired glucose toleranceDesign: 500 mcg twice daily for 4 weeks; no comparison group described; abstract onlyResult: Glucose tolerance improved in halfLabels: No comparison group, Abstract only

All four from the developer's network (St Petersburg and Kyiv). ClinicalTrials.gov: no Pancragen study.

There are four small human data sources, all developer-linked; the Kyiv study was reported three times and counts once; only the patent example used a placebo.

Why are the Kyiv reports counted once?

The same Kyiv team reported the same study three times. The 2010 paper and the 2011 paper describe the same design, measures and results, with 16 people on Pancragen (the control group is 14 in one and 17 in the other). The 2019 congress abstract repeats the group sizes but says the 16 people were injected with 10 mcg into a muscle daily and also took 200 mcg by mouth, a different route from the two full papers. The most likely explanation is one study reported with an error, so it should be counted as one small study, not three. [11], [27], [20]

The 2011 paper's English abstract also mentions “70%”, describing lower night-time melatonin production in people with diabetes. In the full text, 70% is the share of people with diabetes who had low night-time levels of a melatonin breakdown product. It is not a result of Pancragen treatment. [27]

What do those blood-sugar tests measure?

• Fasting blood sugar is measured after a night without food. The Kyiv study used 7.0 mmol/L (126 mg/dL) or higher, on two occasions, to confirm diabetes. [11]
• The glucose tolerance test (OGTT) measures blood sugar at intervals after a standard sugar drink. It shows how well the body clears a sugar load.
• HOMA-IR is a number calculated from fasting blood sugar and fasting insulin that estimates insulin resistance. In the Kyiv study it fell from 8.5 to 6.9 on Pancragen, versus 7.8 to 7.5 on glibenclamide alone. [11]
• HbA1c reflects average blood sugar over about three months, with the most recent weeks counting most, so a large change over a month can show up in it. The Kyiv study measured it only at the start, so it reported no HbA1c result after treatment. [11], [48]

For scale: in the Kyiv study, average fasting blood sugar after 3 weeks of Pancragen was 8.5 mmol/L, still well above the 7.0 mmol/L level the study used to diagnose diabetes. The reports did not measure what matters over years: long-term control, complications, low blood sugar episodes or quality of life. [11]

How might Pancragen work?

The developers' idea is that short peptides act as tissue-specific signals, switching genes on or off in the cells of their target organ. For Pancragen, that means genes that make pancreatic cells mature into insulin-making or enzyme-making cells. The experiments below test pieces of that idea. They are preclinical (in cells, animals and test tubes), and all come from one research network.

What happens in pancreatic cells grown in a dish?

In cell studies, Pancragen raised the activity of genes and proteins linked to cell maturation and renewal in pancreatic cells grown in a dish, especially in cultures grown many times over, which the authors treat as a model of aging. These included Pdx1 and Pax6, master switches that help cells become insulin-making beta cells. [49], [50], [29], [51]

Two cautions apply. The key 2013 paper calls its cells “embryonic” pancreatic cells, but the cell bank that supplies the line it names, MIA PaCa-2, lists it as derived from a pancreatic cancer (carcinoma) in a 65-year-old man. And one aged-cell study found that Pancragen also raised markers of cell division (Ki67 and PCNA) and lowered p53, a protein that can stop damaged cells from dividing. Whether that is healthy renewal or unwanted growth was not tested. [29], [30], [50]

Does it really bind DNA?

That is the proposed mechanism, but it has only been shown in test tubes and computers. Computer models placed Pancragen in DNA's major groove at particular short sequences, and test-tube experiments with DNA and with histone proteins from wheat showed binding. A related study found changes in chemical tags (methylation) on the switches of some pancreatic genes during culture aging. None of this shows the peptide reaching DNA inside a living pancreas. [52], [53], [54], [55], [51]

What did the diabetic rat studies find?

In the patent's rats with diabetes caused by alloxan, a chemical that destroys insulin-making cells, daily injections into the belly cavity lowered blood sugar by 22–38% compared with untreated diabetic rats. By day 84, 36.4% of treated rats had died versus 70% of untreated ones, and blood insulin during treatment was 3.9 times higher. Healthy rats given the peptide did not develop low blood sugar. These are the inventors' own data. [1], [42]

In rats with diabetes caused by streptozotocin, a similar chemical, Pancragen by mouth lowered blood sugar during treatment, and injected Pancragen improved how blood-vessel lining cells behaved but did not change how leaky the small vessels were. Only the abstracts are available, so the doses and group sizes are unknown. [3], [56]

What did the monkey studies find?

The closest model to people is a small study in old female rhesus monkeys: 5 received 50 mcg per animal into a muscle daily for 10 days, and 4 received glimepiride, a sulfonylurea. After a sugar load, blood sugar peaked lower and cleared faster on Pancragen, and the authors describe insulin and C-peptide responses as normalized, with effects still present 3 weeks later. [40], [41]

Fasting blood sugar did not change on Pancragen. The Russian full text reports 3.4 mmol/L before the course and 3.5 during it, no significant change, while glimepiride lowered it from 3.5 to 2.9. The English abstract says both drugs lowered baseline blood sugar, which conflicts with the paper's own results. This guide follows the full text. [40]

Where did the sequence come from?

A 2005 paper says the developers designed the amide form from a stretch shared by insulin-releasing hormones, and a 2010 paper calls it “endogenous”, meaning made naturally in the body. No independent study we found has shown that the body makes it. [42], [57]

Explore every Pancragen experiment in the research library.

What are the risks and unanswered questions?

Is Pancragen safe?

Its safety in people has not been established. The human reports say no side effects were seen, but none described how side effects were collected, the groups were small and the courses lasted 10 days to 4 weeks. [10], [20], [1]

No toxicity study has been published in any species. The patent simply states that the peptide “does not have toxicity”, without methods or numbers. [1] And we found no human data at all for the 1–2 mg daily injections that websites describe.

Could Pancragen make blood sugar drop too low?

This is the most important practical risk. Hypoglycemia, blood sugar that is too low, is a known danger of insulin and sulfonylureas, and every Pancragen study in people with diabetes gave it on top of insulin or diabetes pills. [58], [59], [1], [11]

• In the patent example, insulin doses were cut in 8 of 16 treated patients, and one patient with type 1 diabetes was discharged with a fasting blood sugar of 3.4 mmol/L (61 mg/dL), which is below the 3.9 mmol/L (70 mg/dL) threshold usually used for low blood sugar. The patent does not comment on it. In another case, an 83-year-old taking Pancragen tablets had her gliclazide dose halved after her fasting blood sugar fell to 6 mmol/L on the second day. [2], [58]
• In the institute report, 14 of 24 people with diabetes had their medicine reduced and 8 could manage without it during the study. [10]
• In old monkeys, the comparison drug glimepiride lowered fasting blood sugar and Pancragen did not; no study has tested Pancragen and a sulfonylurea together in animals. [40]

No study reported a low blood sugar episode, but none said how it would have detected one. Low blood sugar typically causes shakiness, sweating, a fast heartbeat, hunger, irritability or confusion, and can become dangerous. Anyone taking insulin, a sulfonylurea such as glibenclamide (glyburide), gliclazide or glimepiride, or other diabetes medicines should agree any addition with the prescriber, check blood sugar more often and never change medicine doses on their own. [60], [59]

Should people with pancreatitis use it?

Not as a response to an attack. Acute pancreatitis usually causes severe, constant pain in the upper belly that often spreads to the back, and doctors confirm it with blood tests showing lipase or amylase at least three times the normal upper limit, or with a scan. It needs urgent medical care. [61], [62]

Pancragen has only been studied in chronic pancreatitis during a quiet spell, in one unpublished report. [10] In community education groups, pancreas bioregulators were suggested to members with raised lipase on GLP-1 weight-loss medicines and during suspected pancreatitis; there is no evidence for that use. In one public second-hand account, a woman with earlier pancreatitis attacks took Pancragen two months after an attack and then had another one; one story cannot show cause, but it is the only harm report we found. [63]

What problems have actually been reported?

Very few, and none formally. Apart from the second-hand pancreatitis account above, no public account described side effects. Community education groups reviewed for this guide contained almost no first-hand reports of anyone using Pancragen, so their silence says nothing about safety. No published case report of harm from Pancragen was found, and no regulator warning names it. [63], [64]

Could product quality change the risk?

Yes. The vials are sold as unregulated “research” chemicals, and no maker has published the sequence, purity, sterility or testing of an injectable Pancragen product that we could find. Pages disagree about whether the product is the amide or the free acid, and one gives a different sequence entirely. In community education groups, members reported that they could not find certificates of analysis and that few labs test bioregulators. Health Canada warns that unauthorized injectable peptides may cause infections or allergic reactions and may not have been made or stored safely. [6], [38], [46]

Is Pancragen legal? Is it FDA-approved?

Checked September 24, 2026. Rules differ by country and change quickly. A “research use only” label does not make a product legal to sell or safe to use.

United States. Pancragen is not an FDA-approved medicine: a search of FDA's approved-drug database found no entry. [65] It is not among the substances nominated for pharmacy compounding (list updated May 14, 2026), not on FDA's list of compounding substances that may pose significant safety risks, and not in the compounding regulation's list of allowed bulk substances. Absence from those lists is neither an approval nor an FDA safety judgment. [66], [67], [68]

Canada. Health Canada's recall and safety-alert search finds no record for Pancragen, including archived records. Its advisories on unauthorized injectable peptides name several sister bioregulators but not Pancragen. Injectable peptides are regulated as prescription drugs in Canada, so selling unauthorized injectable products is illegal whether or not a product is named. [64], [69], [46]

Australia. Pancragen is not named in the June 2026 Poisons Standard, and the Therapeutic Goods Administration's (TGA's) 2026 warnings on unapproved peptides do not name it. A live search of the Australian Register of Therapeutic Goods could not be completed, so we cannot confirm its register status. The TGA says unapproved peptide products “have not been assessed by the TGA for safety, quality or effectiveness”, and that personal importation is permitted only if products are clearly and accurately labelled. Labelling is one condition, so a well-labelled vial is not automatically legal to import. [70], [71], [72]

United Kingdom. A search of UK government sites, which include the medicines regulator (MHRA), found no record for Pancragen or Pankragen. [73]

Russia. The capsules are registered as a dietary supplement (a biologically active food additive), not as a medicine; a Russian drug directory lists a 2015 registration for 0.275 g capsules as active. [4], [15]

Is Pancragen banned in sport? Does it show up on a drug test?

Pancragen is not named on the World Anti-Doping Agency's 2026 list or on the 2027 list that takes effect on January 1, 2027. Category S0 bans at all times any substance “with no current approval by any governmental regulatory health authority for human therapeutic use”, and the 2027 list adds “peptides” to its examples. WADA has not ruled on Pancragen specifically, and a Russian supplement registration is not a medicine approval, so tested athletes should assume S0 can apply. [74], [75]

No published anti-doping test for Pancragen was found, and how long it could be detected is unknown.

Does Pancragen cause cancer?

Nobody knows. There are no long-term human data and no animal cancer studies. In aged pancreatic cells, Pancragen raised markers of cell division and lowered p53, a protein that can stop damaged cells from dividing, and one of the key cell studies used a pancreatic cancer cell line; that neither shows a cancer risk nor rules one out. A claim in a public thread that it cuts pancreatic cancer risk in half came with no source. [50], [29], [30], [28]

Who should be especially cautious?

These groups have no safety data in people. That is a reason for caution, not proof of harm.

• People taking insulin, sulfonylureas or other diabetes medicines. See the low blood sugar section above. [1], [11]
• Type 1 diabetes. Only one small patent example included it, and insulin must never be stopped. [1]
• Suspected or active pancreatitis, or raised lipase or amylase. These need medical assessment first. [61]
• Pregnancy and breastfeeding. The capsule label lists both as reasons not to use it. [4]
• Children and teenagers. The patent example included patients from age 16, but no study has looked at younger people, and this guide is written for adults. [1]
• A history of cancer, including pancreatic cancer. Because of the unanswered growth-signal questions above.
• Competitive athletes. See the anti-doping section above. [74]

Has Pancragen been tested alongside other medicines?

Only in the sense that everyone in the human reports also took their usual treatment: insulin, glibenclamide or gliclazide for diabetes, and standard care for chronic pancreatitis. The reports do not describe interactions beyond the falling medicine doses. Nothing is known about combining Pancragen with metformin, GLP-1 medicines such as semaglutide or tirzepatide, digestive enzymes, blood thinners or other peptides. [1], [11], [10]

GLP-1 medicines carry their own warnings about pancreatitis and about low blood sugar when combined with insulin or sulfonylureas, so adding another glucose-lowering product on top needs particular care. Bring a complete list of everything you take to a pharmacist or doctor. [76], [77]

What should be monitored while using Pancragen?

No regulator has written a monitoring plan for Pancragen. The capsule label only advises talking to a doctor before use, and the developer institute's report recommends taking it in type 2 diabetes “under control of blood glucose”. The injectable vials are sold for laboratory research, with no approved label. What exists is a record of what the small studies measured. It can help you prepare questions for a clinician; it is not a personal testing plan. [4], [10]

What did the human studies check?

• Blood sugar. Every diabetes study measured fasting blood sugar, and most ran a glucose tolerance test before and after the course. [1], [10], [11]
• Insulin and insulin resistance. The Kyiv study measured fasting insulin and HOMA-IR; the forte series added HbA1c, proinsulin and other measures of insulin release. [11], [14]
• Diabetes medicine doses. The patent and the institute report tracked insulin and tablet doses, which were lowered as blood sugar fell. [1], [10]
• General blood tests. The institute report measured blood counts, ESR, blood proteins, potassium, calcium, sodium and blood fats, plus digestive enzymes in intestinal fluid in chronic pancreatitis. [10]
• Side effects. Reported as none, without saying how they were looked for. [10], [20]

The monkey studies also tracked C-peptide, a by-product of the body's own insulin production. [40]

Which measures matter, and why?

In community education groups, one educator who discusses Pancragen points out that it is one of the few bioregulators with a cheap, checkable target, fasting blood sugar and insulin, and suggests measuring before a course and a few weeks after, and stopping after two courses with no change. That is educator advice, not a tested plan. Health Canada advises anyone who has used an unauthorized injectable peptide and has health concerns to talk to a health professional and to report side effects. [46]

What do people in public communities report?

Public accounts are few. English-language Reddit users mention Pancragen mostly while planning or asking questions; the first-hand reports are short and mostly sit on seller or pharmacy pages. Across all of them, nobody posted lab results with dates and units. [78], [79], [80]

What do the positive reports look like?

The only first-hand report on an independent forum came from a person with type 2 diabetes about a week into use, who wrote that it “seems to help blood glucose”, without readings, dose or other medicines. Another person said they were taking it for insulin resistance but gave no result. [78], [81]

On seller pages, two testimonials for a four-product diabetes set that includes Pancragen describe normal blood sugar and weight, one with “sugar from 6.2 to 3.6” without units or test type; both also changed diet or activity. Two anonymous testimonials on a vial seller's page describe better digestion after daily injections, one at “10–20 mg” and one for self-described acute pancreatitis. Seller-selected reviews cannot be checked. [82], [83], [84], [85]

Does everyone notice a difference?

No. A buyer of the capsules wrote that the effect was “not clear yet”. [86] In community education groups, the only two first-hand reports we found both described no benefit: one long-time user of several bioregulators checked pancreas-related lab markers and saw no improvement, and another listed Pancragen among ten bioregulators that were mostly ineffective after repeated courses. Requests in those groups for Pancragen experiences with blood work went unanswered.

What about unwanted effects?

The only harm account was the second-hand pancreatitis attack described above. No one reported low blood sugar or injection-site problems, but so few people described using it that this says little. See the risks. [63]

What do community education groups teach?

The educator who covers Pancragen most fully treats it as an optional add-on in blood-sugar plans, beside better-tested options such as metformin and GLP-1 medicines. Educators give general bioregulator templates (1–2 mg a day for 10–30 days, or 2–5 mg) rather than a Pancragen-specific dose. Some lessons reproduce seller descriptions that focus on digestion; others focus on insulin-making cells. Several lessons and posts treat Pancragen, Suprefort and Pancramin as interchangeable. Members, many of whom have type 2 diabetes and take GLP-1 medicines or insulin, mostly hope it will repair or restart the pancreas. Some advice went beyond any evidence, such as reassuring an insulin user about side effects without mentioning blood-sugar checks, suggesting pancreas bioregulators for raised lipase, and placing Pancragen in a 16-week plan when no source goes beyond a month.

How can you judge a blood-sugar story?

Ask: What else changed: diet, weight, exercise, a new medicine or a changed dose? Was blood sugar measured the same way, at the same time of day, before and after, with units? Was it one reading or many? Capsule or vial, and how much? What happened months later, and was HbA1c checked?

These selected discussions are not a survey of all users, a response rate or a substitute for controlled studies. Several accounts sit on seller pages that choose which reviews to show, and one Reddit post promoting Pancragen carried a discount code. [82], [84], [87]

How does Pancragen compare with Epitalon, Cardiogen, MOTS-c and semaglutide?

Pancragen is discussed alongside other short peptides from the same Russian program, alongside MOTS-c, which people often stack with it for insulin resistance, and alongside semaglutide, the approved medicine many readers with type 2 diabetes already know. The table compares what each one is and how much has been tested in people.

The real differences are in how much has been tested. Semaglutide has large, long placebo-controlled trials in type 2 diabetes and an approved label; Pancragen has four small, short reports from one research network, none measuring HbA1c after treatment. Pancragen, Epitalon and Cardiogen differ by only a few amino acids and come from the same developer, but their human reports differ in routes, outcomes and study design. MOTS-c has mouse data but no human treatment data. No study has compared Pancragen with any of them in people, and combining them has never been tested. Suprefort and Pancramin, which people often mention with Pancragen, are pancreas extracts with no Doserly guide yet (see the common questions).

Common questions about Pancragen

Is Pancragen a pill or an injection?

Both are sold, and they are different products. The original Russian Pancragen is a capsule taken with meals, declaring 100 mcg of peptide complex. Western sellers offer 10–20 mg vials of powder for injection. Most human data come from Pancragen taken by mouth; we found no study of the 1–2 mg daily injections that websites describe. [4], [11], [6] See the two protocol tables.

Is Pancragen the same as Suprefort or Pancramin?

No. Pancragen is a single lab-made peptide (Lys-Glu-Asp-Trp). Suprefort is a natural peptide complex extracted from pancreas tissue, and Pancramin is a peptide extract made from cattle pancreas. They are often sold side by side and sometimes described as interchangeable, but research on one cannot be counted as research on another. [1], [8], [9] Pangluin Forte, a liquid, does list Pancragen among its ingredients, in an unstated amount. [5]

Is Pancragen the same as the PancraGEN test?

No. PancraGEN is also the name of a laboratory test that analyzes fluid from pancreatic cysts to estimate cancer risk. It has nothing to do with the peptide, but the shared name means searches for one often turn up the other. [107], [79]

Can Pancragen replace insulin or diabetes medicine?

The reviewed evidence gives no reason to think so. In every human report, Pancragen was added to insulin or diabetes pills, not used instead of them, and the reported changes in blood sugar were short-term and varied across reports. Stopping insulin in type 1 diabetes can be life-threatening, and lowering any diabetes medicine should be done with the prescriber and more frequent blood-sugar checks. [1], [11] See low blood sugar risks.

Can Pancragen regenerate beta cells or cure diabetes?

No study has shown that in people. The “regeneration” idea comes from raised maturation markers in cells grown in a dish, one of which was a pancreatic cancer cell line, and from diabetic rats. No human study measured beta-cell mass, and the longest human course was 4 weeks. [29], [30], [1], [14] See how it might work.

How long does Pancragen take to work?

There is no reliable answer. The human reports measured blood sugar after 10 days to 4 weeks, and the institute report claims blood sugar normalized within 5–10 days in its treated group. The only independent-forum user described a possible change after about a week. HbA1c can change within weeks, but no report measured it after treatment, so a lasting effect on it has not been shown. [10], [11], [78], [48] See what people reported.

Is it legal to buy Pancragen?

It depends on the country and the product. The capsules are sold as a supplement in Russia. Pancragen is not approved as a medicine in the United States, and in Canada unauthorized injectable peptides are illegal to sell. A “research use only” label does not make a product legal or safe. See the dated legal-status summary. [4], [65], [46]

Is a longer course more likely to work?

Nothing shows that. Courses range from 10 days to one month in the sources, and 60-day or 16-week plans in community discussions go beyond every source. No one has compared course lengths, and longer use raises safety questions that short, small reports cannot answer. [1], [4], [14]

Glossary

Plain explanations of the route, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Amino acid

A small chemical building block. Chains of amino acids make up peptides and proteins.

Animal study

Research in animals such as rats, mice or monkeys. It shows what a substance does in a living body, but results in people can differ.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. It depends heavily on the route. For Pancragen it has not been measured by any route.

Bioregulator

The name a Russian research group uses for very short peptides it believes act on particular tissues. It is a marketing and research label, not a regulatory category.

C-peptide

A substance released in equal amounts with insulin when the body makes its own insulin. Measuring it shows how much insulin the pancreas is producing.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. In the US, federal lists control which bulk ingredients pharmacies may use; being on such a list is not a drug approval.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

Course and cycle

A course is the period of repeated use, such as one month. A cycle is a course plus a planned break before any further use.

Daily total

All the amounts given in one day, added together. For example, 2 capsules of 100 mcg twice daily is a 400 mcg daily total.

Dietary supplement

A product sold as a food additive rather than a medicine. In Russia these are registered with lighter requirements than medicines and do not have to prove they work.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

GLP-1

Glucagon-like peptide-1, a gut hormone that raises insulin after meals. Medicines such as semaglutide act on its receptor.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts. Pancragen's has not been measured.

HbA1c

A blood test that reflects average blood sugar over roughly the past three months. It is the main measure of long-term diabetes control.

HOMA-IR

A number calculated from fasting blood sugar and fasting insulin that estimates insulin resistance. Higher numbers mean more resistance.

Hypoglycemia (low blood sugar)

Blood sugar that is too low, usually below 3.9 mmol/L (70 mg/dL). It can cause shakiness, sweating, a fast heartbeat and confusion, and is more likely with insulin or sulfonylureas.

Impaired glucose tolerance

Blood sugar that rises higher than normal after a sugar drink, but not high enough for diabetes. It is one form of prediabetes.

Insulin resistance

When the body's cells respond less to insulin, so more insulin is needed to keep blood sugar normal. It is common in type 2 diabetes.

Intramuscular (IM)

Injected into a muscle. The patent example and the monkey studies gave Pancragen this way.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition.

Loading phase

Starting with a higher amount for a short period, then lowering it. No Pancragen loading schedule has been tested.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg. Pancragen capsules declare 100 mcg each; injection amounts are usually written in mg.

Glucose tolerance test (OGTT)

A test in which blood sugar is measured at intervals after drinking a standard amount of sugar, usually 75 g. It shows how well the body clears a sugar load.

Oral

Taken by mouth, as a capsule, tablet or liquid.

Pancreatitis

Inflammation of the pancreas. An acute attack causes severe upper belly pain, often spreading to the back, and needs urgent care; chronic pancreatitis is long-lasting damage that can impair digestion.

Peptide

A short chain of amino acids. Pancragen is a chain of four, called a tetrapeptide.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance. For Pancragen, no data exist in any species.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies. In the Pancragen patent example it was a salt-water injection.

Preclinical research

Studies done before research in people: cell studies, test-tube experiments and animal studies.

Reconstitution

Mixing a freeze-dried powder with a sterile liquid so it becomes a solution. How long mixed Pancragen stays usable has not been tested.

FDA, Health Canada and TGA

The medicine regulators discussed in this guide for the United States, Canada and Australia (the Therapeutic Goods Administration). None has approved Pancragen.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. This is the route most injectable Pancragen descriptions use.

Sulfonylurea

A type of diabetes pill, such as glibenclamide (glyburide), gliclazide or glimepiride, that makes the pancreas release more insulin. It can cause low blood sugar.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of drug per unit depends on the vial's concentration.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport.

Explore more of the research

Go deeper into the experiments behind the claims.

Across this guide, the citations include 19 original scientific papers on Pancragen: three small human studies in journals, six animal studies in rats and monkeys, six cell and tissue-culture studies, one test-tube chemistry study and three computer-modelling studies. The patent family and the unpublished 2007 institute report are counted separately. Paper counts are not counts of independent research teams: all come from one research network, and some report the same data more than once.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, patents, an institute report, trial-registry searches, regulatory documents, product labels and published protocol descriptions. We also reviewed public online forums, pharmacy and seller review pages, and community education groups, where people describe their own experiences with Pancragen.

The guide cites 107 sources, including 27 original scientific papers. Each type of source answers a different question. Studies show what researchers measured. Protocol descriptions show how Pancragen is typically used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources